269 related articles for article (PubMed ID: 32383524)
1. Challenges, applications and future directions of precision medicine in prostate cancer - the role of organoids and patient-derived xenografts.
Joshi A; Roberts MJ; Alinezhad S; Williams ED; Vela I
BJU Int; 2020 Jul; 126(1):65-72. PubMed ID: 32383524
[TBL] [Abstract][Full Text] [Related]
2. A synopsis of prostate organoid methodologies, applications, and limitations.
Gleave AM; Ci X; Lin D; Wang Y
Prostate; 2020 May; 80(6):518-526. PubMed ID: 32084293
[TBL] [Abstract][Full Text] [Related]
3. Use of conditional reprogramming cell, patient derived xenograft and organoid for drug screening for individualized prostate cancer therapy: Current and future perspectives (Review).
Cao J; Chan WC; Chow MSS
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35322860
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology.
Golebiewska A; Hau AC; Oudin A; Stieber D; Yabo YA; Baus V; Barthelemy V; Klein E; Bougnaud S; Keunen O; Wantz M; Michelucci A; Neirinckx V; Muller A; Kaoma T; Nazarov PV; Azuaje F; De Falco A; Flies B; Richart L; Poovathingal S; Arns T; Grzyb K; Mock A; Herold-Mende C; Steino A; Brown D; May P; Miletic H; Malta TM; Noushmehr H; Kwon YJ; Jahn W; Klink B; Tanner G; Stead LF; Mittelbronn M; Skupin A; Hertel F; Bjerkvig R; Niclou SP
Acta Neuropathol; 2020 Dec; 140(6):919-949. PubMed ID: 33009951
[TBL] [Abstract][Full Text] [Related]
5. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
Pamarthy S; Sabaawy HE
Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
[TBL] [Abstract][Full Text] [Related]
6. Personalising Prostate Radiotherapy in the Era of Precision Medicine: A Review.
Spence W
J Med Imaging Radiat Sci; 2018 Dec; 49(4):376-382. PubMed ID: 30514554
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer organoids: a potential new tool for testing drug sensitivity.
Vela I; Chen Y
Expert Rev Anticancer Ther; 2015 Mar; 15(3):261-3. PubMed ID: 25603995
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.
Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544
[TBL] [Abstract][Full Text] [Related]
9. Organoids: An intermediate modeling platform in precision oncology.
Jin MZ; Han RR; Qiu GZ; Ju XC; Lou G; Jin WL
Cancer Lett; 2018 Feb; 414():174-180. PubMed ID: 29174804
[TBL] [Abstract][Full Text] [Related]
10. Engineering Prostate Cancer from Induced Pluripotent Stem Cells-New Opportunities to Develop Preclinical Tools in Prostate and Prostate Cancer Studies.
Hepburn AC; Sims CHC; Buskin A; Heer R
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019175
[TBL] [Abstract][Full Text] [Related]
11. A patient-derived explant (PDE) model of hormone-dependent cancer.
Centenera MM; Hickey TE; Jindal S; Ryan NK; Ravindranathan P; Mohammed H; Robinson JL; Schiewer MJ; Ma S; Kapur P; Sutherland PD; Hoffmann CE; Roehrborn CG; Gomella LG; Carroll JS; Birrell SN; Knudsen KE; Raj GV; Butler LM; Tilley WD
Mol Oncol; 2018 Sep; 12(9):1608-1622. PubMed ID: 30117261
[TBL] [Abstract][Full Text] [Related]
12. Establishment and Analysis of Three-Dimensional (3D) Organoids Derived from Patient Prostate Cancer Bone Metastasis Specimens and their Xenografts.
Lee S; Burner DN; Mendoza TR; Muldong MT; Arreola C; Wu CN; Cacalano NA; Kulidjian AA; Kane CJ; Jamieson CAM
J Vis Exp; 2020 Feb; (156):. PubMed ID: 32065165
[TBL] [Abstract][Full Text] [Related]
13. Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer.
Collins A; Miles GJ; Wood J; MacFarlane M; Pritchard C; Moss E
Gynecol Oncol; 2020 Jan; 156(1):251-259. PubMed ID: 31767187
[TBL] [Abstract][Full Text] [Related]
14. Advantages and limitations of 3D organoids and ex vivo tumor tissue culture in personalized medicine for prostate cancer.
Mickova A; Morong M; Levková M; Kurfúrstová D; Kharaishvili G; Überall I; Student V; Student V; Drapela S; Soucek K; Bouchal J
Klin Onkol; 2022; 35(6):473-481. PubMed ID: 36513514
[TBL] [Abstract][Full Text] [Related]
15. Applications of lung cancer organoids in precision medicine: from bench to bedside.
Li H; Chen Z; Chen N; Fan Y; Xu Y; Xu X
Cell Commun Signal; 2023 Dec; 21(1):350. PubMed ID: 38057851
[TBL] [Abstract][Full Text] [Related]
16. Preclinical models for precision oncology.
Ibarrola-Villava M; Cervantes A; Bardelli A
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):239-246. PubMed ID: 29959990
[TBL] [Abstract][Full Text] [Related]
17. Applications of Organoids for Cancer Biology and Precision Medicine.
Lo YH; Karlsson K; Kuo CJ
Nat Cancer; 2020 Aug; 1(8):761-773. PubMed ID: 34142093
[TBL] [Abstract][Full Text] [Related]
18. [Application of Organoids in Lung Cancer Precision Medicine].
Jia Z; Liang N; Li S
Zhongguo Fei Ai Za Zhi; 2020 Jul; 23(7):615-620. PubMed ID: 32702796
[TBL] [Abstract][Full Text] [Related]
19. Organoid technology in cancer precision medicine.
Xia X; Li F; He J; Aji R; Gao D
Cancer Lett; 2019 Aug; 457():20-27. PubMed ID: 31078736
[TBL] [Abstract][Full Text] [Related]
20. Emerging organoid models: leaping forward in cancer research.
Fan H; Demirci U; Chen P
J Hematol Oncol; 2019 Dec; 12(1):142. PubMed ID: 31884964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
